


## SYNTHESIS OF (+)-8 $\alpha$ ,9-SECOARTEMISININ AND RELATED ANALOGS

Mitchell A. Avery\*, Wesley K. M. Chong, and George Detre  
Bio-Organic Chemistry Laboratory, Life Sciences Division, SRI International, 333 Ravenswood Avenue,  
Menlo Park, California 94025


**Abstract:** An efficient synthesis of (+)-8 $\alpha$ ,9-secoartemisinin **2**, a ring-D cleaved, tricyclic analog of (+)-artemisinin **1**, has been accomplished. Dioxetane **Z**, produced upon ozonolysis of vinyl-silane **5** in methanol, was intercepted with acid to provide the stable bicyclic peroxy-aldehyde **9**, which was readily converted to the title compound(s).

The sesquiterpene (+)-artemisinin **1** displays impressive activity against the widespread threat of resistant strains of *Plasmodium falciparum*.<sup>1</sup> Geo-economic and pharmacodynamic considerations further stimulate the ongoing search for the molecular basis of action and minimum structural requirements for high potency in this class of drugs.<sup>2</sup> Increasing efforts to achieve an efficient total synthesis<sup>3</sup> now provide methodology suitable to the synthesis of numerous analogs.<sup>4</sup>




As part of our program, we have employed a disconnective approach to understanding the requirements for antimalarial activity of **1**. Analogs of **1** that lack the 4,5-bond (A-ring seco) display conformational flexibility about the trioxane/lactone rings and a concomitant reduction of activity.<sup>5</sup> A similar conceptual scission of the D-ring (bond 8 $\alpha$ ,9) provides derivatives, such as **2**, that must mimic the relative orientation of the A,B, and C rings of **1** and are thus of considerable interest.<sup>6</sup> As described below, we have employed vinylsilane ozonolysis methodology<sup>7</sup> to install the crucial functional arrangement for the construction of **2**.

The synthesis of **2** is shown in Scheme 1. Reaction of dimethyl(methoxy)silyl(trimethylsilyl)methyl-lithium<sup>8</sup> with the chiral ketone **3** in pentane afforded the E/Z vinylsilane **4** in 50% yield (93% based on recovered **3**). Hydrolysis of **4** with aqueous oxalic acid impregnated silica gel in dichloromethane provided the requisite keto-silane **5** in 81% yield. Upon exposure of **5** to ozone in CH<sub>2</sub>Cl<sub>2</sub> at low temperature, the stable silyl-peroxy aldehyde **6** was the sole product. In contrast, ozonolysis of **5** in methanol led to clean production of the dioxetane **Z**, as was evidenced by NMR ( $\delta$ 6.0, CDCl<sub>3</sub>). The dioxetane **Z** was reasonably stable but slowly underwent cycloreversion to the diketone **13** on standing at room temperature for several hours. However, if boron trifluoride etherate was added directly to the ozonolysis mixture, then conversion to a stable bicyclic aldehyde **9** was witnessed (69% isolated yield). Assignment of structure **9** to this material rested on NMR (APT, COSY, HETCOR, NOESY)<sup>9</sup> and was recently confirmed by analogy to parallel studies by another group in a racemic system lacking the 8 $\alpha$ -methyl group.<sup>10</sup>

Scheme 1<sup>a</sup>

<sup>a</sup>Key: (a) MeOMe<sub>2</sub>SiCH<sub>2</sub>SiMe<sub>3</sub>, t-BuLi, pentane; (b) aq. oxalic acid, silica gel, CH<sub>2</sub>Cl<sub>2</sub>; (c) O<sub>3</sub>/O<sub>2</sub>, MeOH, -78°C; (d) O<sub>3</sub>/O<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78°C; (e) CDCl<sub>3</sub>, 23°C; (f) moist CHCl<sub>3</sub>, TFA; (g) c followed by BF<sub>3</sub> etherate; (h) NaBH<sub>4</sub>, MeOH, 0°C; (i) BF<sub>3</sub> etherate, MeOH, (MeO)<sub>3</sub>CCH<sub>3</sub>; (j) RCOX, Amberlyst-15, solvent; (k) RCOX, DMAP, CH<sub>2</sub>Cl<sub>2</sub>; (l) p-TsA, CH<sub>2</sub>Cl<sub>2</sub>.

The aldehyde **9** proved useful for conversion to 8a,9-secoartemisinin **2**, or to a variety of other analogs. Treatment of **9** in propionic anhydride, with or without co-solvent, with Amberlyst-15 gave **2** in 30% yield.<sup>11</sup> The reaction was successful with acetic anhydride as well, affording **2a** in 35% yield,<sup>12</sup> but failed with benzoic anhydride. Reduction of **9** with sodium borohydride in methanol provided the alcohol **10**, which upon brief treatment with pTsA in CH<sub>2</sub>Cl<sub>2</sub> was converted directly to the tricyclic trioxane **11** in 79% yield.<sup>13</sup> In an effort to improve upon the conversion of **5** to **2** and make the route applicable with other acylating reagents (for the production of analogs), hydrolysis of the dioxetane **Z**, or of the silyl-peroxide **6**, to the tricyclic alcohol **8** was examined. Under a variety of conditions (e.g., TFA/CDCl<sub>3</sub> or THF/aq. HCl), **Z** gave rise to a chromatographically inseparable mixture of **8**, **8a**, and diketone **13** (1:2:1 ratio, respectively), from which **13** could be removed by bisulfite wash. Aldehyde **6** underwent hydrolysis under neutral conditions (aq. methanol) to give a similar mixture of **8/8a/13**. Upon treatment of the resultant 1:2 mixture of **8/8a** (from **Z**) with propionic anhydride and DMAP in CH<sub>2</sub>Cl<sub>2</sub>, the only isolable products were **2** (20%) and **13** (60%). Similar results were observed under these conditions with benzyl chloroformate, which furnished **2b** (confirmed by x-ray crystallography) in 21% yield<sup>14</sup>, or with acetic anhydride (**2a**, 24%). The unwanted occurrence of the diketone **13** is presumably the product of a fragmentation reaction:



Treatment of either **6**, **Z**, or **9** in methanol with acid and a dehydrating agent (trimethylorthoacetate) gave rise to a mixture of **9** (20%) and the acetal **12** (4:1 mixture of diastereomers, 15% yield).<sup>15</sup> Equilibration of **9** with catalytic acid in dry CH<sub>2</sub>Cl<sub>2</sub> provided **12**, but with attendant fragmentation to **13** (3:2:1 ratio of **13:9:12**, respectively).

In summary, a wide variety of optically active analogs of artemisinin **1** are now readily accessible by this methodology. Studies in progress focus on the synthesis of new analogs, for structure-activity relationship studies, derived from **2a** by ester-enolate alkylation. *In vitro* antimalarial bioassay of **2**, **2a**, **2b**, **9**, **11**, and **12** is in progress and will be reported in due course.

**Acknowledgments.** We thank the U.S. Army Drug Development Program for Contract DAMD17-88-C-8048 (Contribution No. 1863), Drs. Engle and Milhous of WRAIR, and Prof. P. A. Grieco for the X-ray data.

#### References and Notes

1. C. Shen and L. Zhuang, *Medical Research Rev.*, **4**, 58 (1984); Qinghaosu Research Group, *Sci. Sin.*, **23**, 380 (1980).
2. UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases, Abstracts of the Fourth Meeting Sci. Working Group Chemother. Malaria, Oct. 1981; *idem*, Seventh Programme Report, Tropical Disease Research (TDR), Chap. 2, 1983-1984.
3. M. A. Avery, C. Jennings-White, and W. Chong, *Tetrahedron Lett.*, **40**, 4629 (1987); X. Xu, J. Zhu, D. Huang, and W. Zhou, *Tetrahedron*, **42**, 818 (1986); G. Schmid and W. Hofheinz, *J. Amer. Chem. Soc.*, **105**, 624 (1983); M. Jung, H. ElSohly, E. Croom, A. McPhail, and D. McPhail, *J. Org. Chem.*, **51**, 5417 (1986); F. Binns and T. Wallace, *Tetrahedron Lett.*, **9**, 1125 (1989); G. Clark, M. Nikaido, C. Fair, and J. Lin, *J. Org. Chem.*, **50**, 1994 (1985).
4. M. A. Avery, C. Jennings-White, and W. Chong, *J. Org. Chem.*, **54**, 1792 (1989); J. Kepler, A. Philip, Y. Lee, M.

- Morey, and F. Carroll, *J. Med. Chem.*, **31**, 713 (1988); Y. Imakura, T. Yokoi, T. Yamagishi, J. Koyama, H. Hu, D. McPhail, A. McPhail, and K. Lee, *J. Chem. Soc. Chem. Comm.*, 372 (1988).
5. W. Inman, M. A. Avery, W. Chong, and P. Crews, accepted for publication in *J. Org. Chem.*. 4,5-secoartemisinin derivatives exist in an array of conformers in solution (NMR), while X-ray data show a chair-chair-chair conformation.
6. Energy minimization (MMP2) of several conformational isomers of artemisinin (resulting from rotation about the C1-O2-O3-C4 dihedral angle) demonstrates a clear preference for the conformer corresponding to the solid-state structure (X-ray) as well as the solution structure (NOESY). Unlike the 4,5-seco derivatives, 8a,9-scission provides analogs (type **2**) having only one tricyclic conformation that nicely overlaps with the A-B-C rings of the natural product (**1**).
7. M. A. Avery, C. Jennings-White, and W. Chong, *J. Org. Chem.*, **54**, 1789 (1989).
8. T. F. Bates and R. D. Thomas, *J. Org. Chem.*, **54**, 1784 (1989).
9. Crystals of **9** from hexane, m.p. 100-102°C.  $[\alpha]_D^{23} = +317^\circ$  (c = 1.18, CDCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.90 (ddd, J = 4, 12, 14.5 Hz, 1H, 11α), 0.94 (d, J = 6.4 Hz, 3H, 8α-Me), 1.19 (d, J = 1.2 Hz, 3H, 4β-Me), 1.26 (dddd, J = 2.8, 3, 12, 12 Hz, 1H, 7α), 1.28 (m, 1H, 10β), 1.32 (m, 1H, 9α), 1.52 (dddd, J = 1.5, 12, 12, 14.5 Hz, 1H, 6β), 1.66 (dddd, J = 1.5, 4, 6.5, 14.5 Hz, 11β), 1.69 (m, 1H, 10α), 1.85 (dddd, J = 2, 3, 8, 14.5 Hz, 1H, 6α), 1.93 (m, 1H, 9β), 1.94 (dddd, J = 1.2, 2, 12, 14.5 Hz, 1H, 5α), 2.07 (ddd, J = 1.5, 8, 14.5 Hz, 1H, 5β), 2.18 (dddq, J = 4, 6.4, 12, 12 Hz, 1H, 8β), 3.34 (s, 3H, 4α-OMe), 9.51 (d, J = 2.8 Hz, 1H, 1β-CHO). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 19.6 (C-4β), 20.4 (C-8αMe), 21.9 (C-6), 22.0 (C-10), 30.2 (C-9), 32.3 (C-8), 35.2 (C-11), 40.5 (C-5), 49.1 (OMe), 56.6 (C-7), 91.8 (C-1), 108.6 (C-4), 198.2 (C-1β-CHO).
10. C. W. Jefford, J. Velarde, and G. Bernardinelli, *Tetrahedron Lett.*, **30**(34), 4485 (1989).
11. Pure **2** isolated as an oil,  $[\alpha]_D^{22} = +26.3^\circ$  (c = 1.90, hexane). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.97 (d, J = 6.3 Hz, 3H, 8α-Me), 0.99 (m, 1H, 9α), 1.20 (t, J = 7.6 Hz, 3H), 1.26 (m, 2H), 1.38 (s, 3H, 4-Me), 1.39 (ddd, J = 6.6, 11.5, 11.5 Hz, 1H, 7α), 1.44 (m, 1H, 8β), 1.51 (dddd, J = 4.8, 11.5, 13.4, 13.8 Hz, 1H, 6β), 1.62 (m, 2H), 1.91 (dddd, J = 3.1, 3.5, 6.6, 13.8 Hz, 1H, 6α), 2.02 (ddd, J = 3.1, 4.8, 14.6 Hz, 1H, 5β), 2.14 (ddd, J = 2, 3.5, 10.1 Hz, 1H, 11β), 2.39 (ddd, J = 4.1, 13.4, 14.6 Hz, 1H, 5α), 2.47 (q, J = 7.6 Hz, 2H), 6.45 (s, 1H, 12β).
12. Pure **2a** isolated as an oil,  $[\alpha]_D^{21} = +9.3^\circ$  (c = 1.50, hexane). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.97 (d, J = 6.3 Hz, 3H, 8α-Me), 0.98 (m, 1H, 9α), 1.25 (m, 2H, 11α/10β), 1.39 (ddd, J = 6.8, 11.3, 11.3 Hz, 1H, 7α), 1.39 (s, 3H, 4-Me), 1.45 (m, 1H, 8β), 1.52 (ddd, J = 4.8, 11.3, 13.5 Hz, 1H, 6β), 1.63 (m, 2H, 9β/10α), 1.91 (dddd, J = 1.2, 3.5, 6.6, 13.9 Hz, 1H, 6α), 2.02 (ddd, J = 3, 4.8, 14.5 Hz, 1H, 5β), 2.14 (m, 1H, 11β), 2.20 (s, 3H, 12α-OAc), 2.39 (ddd, J = 4, 13.2, 14.5 Hz, 1H, 5α), 6.44 (s, 1H, 12β). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 170.4 (-OAc), 104.5 (C-4), 88.3 (C-12), 83.1 (C-1), 51.6 (C-7), 37.6 (-OAc), 36.1 (C-5), 34.6 (C-11), 33.9 (C-6), 25.9 (4-Me), 24.9 (C-10), 22.1 (C-9), 21.4 (C-8), 20.1 (8-Me).
13. Crystals of **11** from -78°C pentane, m.p. 69-71°C.  $[\alpha]_D^{22} = +88.8^\circ$  (c = 0.267, CDCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.97 (m, 1H, 9α), 0.98 (d, J = 6.1 Hz, 3H, 8α-Me), 1.23 (dddd, J = 3, 4.5, 14.2, 14.2 Hz, 1H, 10β), 1.30 (ddd, J = 3.3, 13.5, 14.2 Hz, 1H, 11α), 1.34 (s, 3H, 4-Me), 1.37 (m, 2H), 1.80 (ddd, J = 3, 4, 13.5 Hz, 1H, 11β), 1.88 (dddd, J = 3.3, 3.3, 6.3, 14 Hz, 1H, 6α), 2.01 (ddd, J = 3.3, 4.5, 14.5 Hz, 1H, 5β), 2.42 (ddd, J = 3.3, 13.4, 14.5 Hz, 1H, 5α), 4.03 (dd, J = 1.6, 11 Hz, 1H, 12α), 4.20 (d, J = 11 Hz, 1H, 12β).
14. Crystals of **2b** from hexane, m.p. 110°C.  $[\alpha]_D^{22} = -17.5^\circ$  (c = 0.37, CDCl<sub>3</sub>). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.98 (d, J = 6.2 Hz, 3H, 8α-Me), 1.00 (m, 1H, 9α), 1.27 (m, 2H), 1.38 (ddd, J = 6.2, 11.2, 11.2 Hz, 1H, 7α), 1.40 (s, 3H, 4-Me), 1.44 (m, 1H, 8β), 1.48 (dddd, J = 5, 11.2, 13.2, 13.5 Hz, 1H, 6β), 1.63 (m, 2H), 1.91 (dddd, J = 3.5, 3.8, 6.2, 13.5 Hz, 1H, 6α), 2.03 (ddd, J = 3.5, 5, 14.7 Hz, 1H, 5β), 2.20 (br d, J = 10.4 Hz, 1H, 11β), 2.40 (ddd, J = 3.8, 13.2, 14.7 Hz, 1H, 5α), 5.24 (s, 2H), 6.31 (s, 1H, 12β), 7.38 (m, 5H). The structure of **2b** was confirmed by single crystal x-ray crystallographic techniques and will be reported in a fully detailed account.
15. Pure **12** isolated as an oil,  $[\alpha]_D^{21} = -5.4^\circ$  (c = 1.05, hexane). <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>): δ 0.72 (m, 1H, 9α), 0.73 (d, J = 6.4 Hz, 3H, 8α-Me), 0.98 (mq, J = 6.4 Hz, 1H, 8β), 1.07 (m, 1H, 10β), 1.11 (m, 1H, 11α), 1.14 (m, 1H, 7α), 1.27 (dddd, J = 5, 11.5, 13.5, 14.5 Hz, 1H, 6β), 1.29 (s, 3H, 4-Me), 1.30 (m, 1H, 9β), 1.34 (m, 1H, 10α), 1.59 (dddd, J = 3, 4, 7, 14.5 Hz, 1H, 6α), 1.72 (ddd, J = 3, 5, 14.5 Hz, 1H, 5β), 2.35 (ddd, J = 4, 13.5, 14.5 Hz, 1H, 5α), 2.66 (ddd, J = 2, 3.5, 11 Hz, 1H, 11β), 3.51 (s, 3H, 12α-OMe), 4.95 (s, 1H, 12β).